Department of Health and Human Services, National Institutes of Health’s Office of Rare Diseases, the National Institute of Neurological Disorders and Stroke, FDA Center for Drug Evaluation and Research

Concurrent with the workshop on Newborn Screening, this meeting took place in an adjacent room. The purpose of the meeting was to review and discuss the difficulties in translating preclinical studies in animals to clinical trials in humans.

Individuals with IEM have a range of functioning, which may vary with the specific mutation. The neurological effects of disease over time are virtually unknown. The presenters noted that researching inborn errors of metabolism (IEM) is made particularly challenging by their rarity, ethical issues in studying children, and the fact that it is extremely difficult to study the impact of disease and its treatment on the brain. What is clear is that IEM, including MSUD, are diseases which affect the nervous system. As such, the individual may not be functioning optimally even when well controlled.

The opening speaker noted that while attempts to treat IEM with stem cell transplant or enzyme enhancement have been unsatisfactory to date, advances in biology and technical tools used to manipulate cells have occurred.

Lay organizations such as ours are invaluable to scientists as parents and patients teach the doctors, conduct fundraising to support research, and act as advocates to legislators. The speaker noted that organizations which raise money for research must have a scientific advisory board to review grant applications. An independent assessment is needed to evaluate the scientific credibility of the proposed research and to balance the risk with potential benefit.

The room was filled with physicians, researchers, public health officials, psychologists, genetic counselors, representatives of support groups, pharmacologists, and more. As I observed all these individuals, organizations, and medical institutions speak of the need to collaborate, I felt a real hope that a breakthrough will occur.

In The Professional Journals

A Patient with MSUD: Acute Management with Sodium Phenylacetate/Sodium Benzoate and Sodium Phenylbutyrate

Read More

Sweet Odyssey

Artur Santos was born on January 18, 2002, the second son of Soraya and Idario Santos. They never imagined how their lives were about change as the second baby arrived.

Read More

Cambrooke Foods Hosts Local Event

Cambrooke has been doing cooking demonstrations, social meet ups and educational events for patients, their families and the clinician’s that support them for many years.

Read More

Our Story

On April 23 2015, our precious firstborn son Eliyahu Tuvia was born in Jacksonville, FL. All seemed well and we took our bundle of joy home.

Read More

NBS-MSUD Connect: Advancing MSUD Research And More


Rare disease registries have received attention in recent years because of the many ways in which they can benefit the rare disease community.

Read More


In the 2016 survey of the membership of the MSUD Family Support Group, research for improved treatments and potential cure was rated “most important” by 90% of the responding members.

Read More


A Child's Life

Subscribe to our mailing list

Signup To Our Newsletter Signup with your email address to receive news and updates